Trial Profile
A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects with Multiple System Atrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Verdiperstat (Primary)
- Indications Multiple system atrophy
- Focus Adverse reactions; Pharmacodynamics
- Sponsors AstraZeneca
- 31 Jul 2019 Results presented in a Biohaven Pharmaceutical Holding Company media release.
- 06 Jun 2018 Population pharmacokinetic model for AZD3241 was developed using data from one phase 1 MAD study in healthy subjects (study 02, D0490C00002, NCT00914303), and one phase 2 safety and tolerability study (study 23,D0490C00023, NCT02388295), results published in the Journal of Clinical Pharmacology
- 24 Mar 2018 Data from one phase I study (NCT00914303) and one phase II study in Multiple System Atrophy (NCT02388295) trial was used to develop PopPK model, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics